Renal cell carcinoma (RCC) metastasis is one of the most common hypervascular metastasis types in the liver. Liver metastases develop in 20-30% of patients with RCC. Clear cell RCC is the subtype most frequently producing hypervascular metastases. It demonstrates intense arterial phase enhancement and portal venous phase washout. Late metastases can occur years after nephrectomy — thus long-term follow-up is required. Primary kidney tumor history is key to diagnosis.
Age Range
40-75
Peak Age
60
Gender
Male predominant
Prevalence
Uncommon
RCC (especially clear cell type) activates the HIF-α pathway due to VHL gene mutation and exhibits high VEGF expression. This leads to intense neoangiogenesis in both primary tumor and metastases — the source of hypervascular character. Metastasis develops hematogenously: renal vein → IVC → hepatic artery/portal vein. A unique feature of RCC is its ability to metastasize late — liver metastases can appear 10-20 years after nephrectomy. The dense lipid and glycogen content of clear cell RCC causes low attenuation on CT and characteristic signal changes on MRI.
A hypervascular liver lesion with intense arterial phase enhancement combined with known RCC or nephrectomy history is the signature finding of RCC metastasis. Due to RCC's ability to produce late metastases, even nephrectomy years prior should be queried in history. Surgical resection or ablation may be curative in solitary metastases.
Intense, usually homogeneous enhancement in arterial phase. The most defining CT finding of clear cell RCC metastases. Small lesions enhance homogeneously, large lesions heterogeneously (central necrosis).
Report Sentence
Hypervascular lesion(s) demonstrating intense arterial phase enhancement are seen in the liver, consistent with metastasis in the context of known RCC history.
Portal venous phase washout — after arterial enhancement, lesions become iso/hypodense relative to surrounding parenchyma. Reflects hypervascular metastasis dynamics.
Report Sentence
The lesions demonstrate washout in the portal venous phase.
Moderate to marked hyperintensity on T2. Clear cell RCC metastases may show brighter T2 signal than other metastasis types (high water + glycogen content).
Report Sentence
The lesions demonstrate hyperintense signal on T2-weighted sequences.
Generally hypointense or isointense on T1. Focal T1 hyperintensity may be seen with intratumoral hemorrhage — but unlike the diffuse T1 hyperintensity of melanoma metastasis, it is focal and heterogeneous.
Report Sentence
The lesions show iso/hypointense signal on T1-weighted sequences; focal hyperintense areas may be consistent with intratumoral hemorrhage.
Intense arterial phase enhancement on MRI dynamic series — hypervascular pattern parallel to CT. Gadolinium-enhanced MRI is more sensitive than CT for detecting small metastases.
Report Sentence
Lesions demonstrating intense arterial phase enhancement on MRI dynamic series are seen in the liver.
RCC metastases show variable echogenicity on US: may be hypoechoic, hyperechoic, or mixed. Increased vascularity may be seen on Doppler due to hypervascularity. Although US is a first-line tool for follow-up and detection, it is not as sensitive as CT/MRI.
Report Sentence
Lesion(s) with variable echogenicity are seen in the liver with increased vascularity on Doppler.
Criteria
Most common type (70-80%). VHL mutation, intense VEGF expression. Pronounced hypervascular character.
Distinct Features
Most hypervascular type — most intense arterial phase enhancement. Bright T2 signal (glycogen/lipid). Good response to anti-VEGF therapy such as sunitinib/pazopanib.
Criteria
Less common (10-15%). Less vascular than clear cell type.
Distinct Features
Hypovascular metastasis pattern — weak arterial phase enhancement. Unlike clear cell type, may be confused with other hypovascular metastases on CT.
Criteria
Appears 5-20 years after nephrectomy. A biological feature unique to RCC — not seen in most cancer types.
Distinct Features
Unexpected liver lesion detected when patient is considered 'cured'. Etiology may be missed if nephrectomy history is not queried. Metastasectomy may be curative in solitary lesions.
Distinguishing Feature
Melanoma metastasis shows diffuse T1 hyperintensity (melanin paramagnetic effect) — RCC metastasis is generally T1 hypointense. Both metastases are hypervascular but primary tumor history (skin vs kidney) and T1 signal pattern are distinguishing.
Distinguishing Feature
Neuroendocrine metastasis is also hypervascular. Distinguished by clinical context (carcinoid syndrome, flushing, diarrhea) and biochemical markers (chromogranin A, 5-HIAA). These markers are normal in RCC.
Distinguishing Feature
HCC develops in cirrhotic liver and is usually solitary. Shows hypointensity on hepatobiliary phase MRI. RCC metastasis occurs in non-cirrhotic liver, usually with nephrectomy history.
Distinguishing Feature
Hemangioma shows peripheral nodular enhancement with centripetal fill-in (slow fill). RCC metastasis shows diffuse arterial enhancement (rapid fill). Hemangioma is very bright on T2 (light bulb sign) while RCC metastasis is moderately hyperintense.
Urgency
urgentManagement
surgicalBiopsy
Not NeededFollow-up
3-monthBiopsy is generally unnecessary for RCC liver metastasis — known primary tumor history and characteristic hypervascular imaging pattern suffice for diagnosis. Surgical resection or ablation (RFA/MWA) may be curative in solitary or oligometastatic disease and significantly extends survival. Systemic therapy is applied for multiple metastases: anti-VEGF (sunitinib, pazopanib, bevacizumab), mTOR inhibitors (temsirolimus, everolimus), immunotherapy (nivolumab + ipilimumab, pembrolizumab). At least 10 years of follow-up after nephrectomy is recommended due to late metastasis risk. Treatment response should be evaluated with CT/MRI at 3-month intervals.
Surgical resection or ablation may be considered for isolated liver metastasis. Tyrosine kinase inhibitors (sunitinib, pazopanib) and immunotherapy (nivolumab + ipilimumab) are systemic treatment options. Long-term follow-up after nephrectomy is important due to late metastasis risk.